Literature DB >> 27168099

Prevalence and implications of cytochrome P450 substrates in Massachusetts hospital discharges.

T H McCoy1,2, V M Castro1,3,4, A Cagan1,3,4, A M Roberson1,2, R H Perlis1,2.   

Abstract

The cytochrome P450 (CYP450) system of drug-metabolizing enzymes may contribute to individual variation in drug response. We examined prevalence of CYP450 substrates at hospital discharge for patients in two cohorts: insurance claims of Massachusetts residents and the medical records of two academic medical centers. The claims cohort included 47 473 individuals (38.2%) treated with at least one CYP450 2D6, 2C19, 3A4 or 1A2 substrate. The electronic medical records cohort included 45 905 individuals (57.4%) treated with at least one substrate. In adjusted models, substrates of CYP450 2D6 and 2C19 were associated with greater risk for 90-day readmission in both cohorts (odds ratios of 1.104 and 1.128 (P<0.001), respectively). Presence of any CYP450 substrate was associated with increased monthly medical costs (+$397, P<0.003). These analyses of more than 300 000 admissions using two different cohorts and data types indicate that CYP450 substrates are associated with greater readmission rates and greater health-care cost.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27168099     DOI: 10.1038/tpj.2016.24

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  13 in total

Review 1.  Predicting in vivo drug interactions from in vitro drug discovery data.

Authors:  Larry C Wienkers; Timothy G Heath
Journal:  Nat Rev Drug Discov       Date:  2005-10       Impact factor: 84.694

Review 2.  Polymorphism of human cytochrome P450 enzymes and its clinical impact.

Authors:  Shu-Feng Zhou; Jun-Ping Liu; Balram Chowbay
Journal:  Drug Metab Rev       Date:  2009       Impact factor: 4.518

Review 3.  A systematic review and meta-analysis of pharmacist-led fee-for-services medication review.

Authors:  Ernieda Hatah; Rhiannon Braund; June Tordoff; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

4.  How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping.

Authors:  Paul Verbeurgt; Tyler Mamiya; Jessica Oesterheld
Journal:  Pharmacogenomics       Date:  2014-04       Impact factor: 2.533

Review 5.  Genomics and drug response.

Authors:  Liewei Wang; Howard L McLeod; Richard M Weinshilboum
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

6.  A drug burden index to define the functional burden of medications in older people.

Authors:  Sarah N Hilmer; Donald E Mager; Eleanor M Simonsick; Ying Cao; Shari M Ling; B Gwen Windham; Tamara B Harris; Joseph T Hanlon; Susan M Rubin; Ronald I Shorr; Douglas C Bauer; Darrell R Abernethy
Journal:  Arch Intern Med       Date:  2007-04-23

7.  Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people: a population-based study.

Authors:  Iacopo Cancelli; Gian Luigi Gigli; Antonella Piani; Barbara Zanchettin; Francesco Janes; Adriana Rinaldi; Mariarosaria Valente
Journal:  J Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.153

8.  The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians.

Authors:  K P Kerr; K E Mate; P J Magin; J Marley; N P Stocks; P Disler; C D Pond
Journal:  J Clin Pharm Ther       Date:  2014-04-07       Impact factor: 2.512

9.  Stratification of risk for hospital admissions for injury related to fall: cohort study.

Authors:  Victor M Castro; Thomas H McCoy; Andrew Cagan; Hannah R Rosenfield; Shawn N Murphy; Susanne E Churchill; Isaac S Kohane; Roy H Perlis
Journal:  BMJ       Date:  2014-10-24

Review 10.  Understanding and preventing drug-drug and drug-gene interactions.

Authors:  Cara Tannenbaum; Nancy L Sheehan
Journal:  Expert Rev Clin Pharmacol       Date:  2014-04-19       Impact factor: 5.045

View more
  1 in total

1.  Stratified delirium risk using prescription medication data in a state-wide cohort.

Authors:  Thomas H McCoy; Victor M Castro; Kamber L Hart; Roy H Perlis
Journal:  Gen Hosp Psychiatry       Date:  2021-05-07       Impact factor: 7.587

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.